Bharat Biotech’s Rotavirus vaccine gets WHO Prequalification

It is the only rotavirus vaccine in the world to be delivered in a 0.5 ml dose volume; rotavirus is the leading cause of severe diarrhoea among children less than five years of age around the world

Bharat Biotech’s Rotavirus vaccine gets WHO Prequalification

Photo for representation. — iStock

Tribune News Service

New Delhi, August 2

Bharat Biotech on Monday announced that the World Health Organisation (WHO) has awarded prequalification to its rotavirus vaccine, ROTAVAC 5D, a

unique rotavirus vaccine formulation that can be administered without a buffer.

Its low dose volume (0.5 mL) facilitates easy vaccine logistics, cold chain management and low biomedical waste disposal post-vaccination.

It is used for the prevention of rotavirus infection, which is prevalent in infants and young children.

WHO Prequalification enables the procurement of ROTAVAC 5D by UN agencies namely UNICEF and PAHO (Pan American Health Association).

The WHO prequalification of ROTAVAC 5D will fast-track global access to this life saving vaccine.

Suchitra Ella, Joint Managing Director, Bharat Biotech, said, “ROTAVAC and its new variant ROTAVAC 5D are projects conceived, innovated, and executed in India; in collaboration with Indian and Global partners. This is the culmination of a 30 year effort to develop a novel rotavirus vaccine, resulting in a major advancement in Rotavirus disease prevention and reasserts India’s leadership in developing and introducing rotavirus vaccines for the world.”

Today’s announcement is an important step to further strengthen and fulfil Bharat Biotech’s vision to address neglected diseases, she said.

Bharat Biotech developed the first generation, rotavirus vaccine, ROTAVAC under a Public-Private Partnership with the Department of Biotechnology, Government of India, and 16 other international partners, making it the largest ever social innovation project for public health.

In the developing world, ROTAVAC has been instrumental in addressing deaths due to rotavirus infection.

Bharat Biotech has so far supplied more than 250 million doses of ROTAVAC.

Rotavirus is the leading cause of severe diarrhoea among children less than five years of age around the world, resulting in more than 200,000 deaths and 2 million hospitalisations worldwide. Vaccinations are an important part of global public health efforts to meet the Sustainable Developmental Goals of UNDP.

Tribune Shorts

Top Stories

Justin Trudeau wins Canada election, falls short of majority

Justin Trudeau wins Canada election, falls short of majority

Liberals leading or elected in 157 seats — exactly the numbe...

31 more die of Covid in Punjab as national active cases lowest in 6 months

31 more die of Covid in Punjab as national active cases lowest in 6 months

National Covid recovery rate recorded at 97.75 per cent

New CM Channi promises thinner power bills, free water in election-bound Punjab

New CM Channi promises thinner power bills, free water in election-bound Punjab

Asks Centre to withdraw farm laws | Randhawa, Soni Deputy CM...

Cities

View All